In the past week, MBIO stock has gone down by -33.48%, with a monthly decline of -49.75% and a quarterly plunge of -45.85%. The volatility ratio for the week is 17.05%, and the volatility levels for the last 30 days are 14.37% for Mustang Bio Inc The simple moving average for the past 20 days is -30.56% for MBIO’s stock, with a -70.85% simple moving average for the past 200 days.
Is It Worth Investing in Mustang Bio Inc (NASDAQ: MBIO) Right Now?
MBIO has 36-month beta value of 1.57. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBIO is 7.58M, and currently, short sellers hold a 5.13% ratio of that float. The average trading volume of MBIO on April 09, 2024 was 153.87K shares.
MBIO) stock’s latest price update
Mustang Bio Inc (NASDAQ: MBIO) has experienced a decline in its stock price by -8.41 compared to its previous closing price of 0.76. However, the company has seen a fall of -33.48% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at -42.06% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.45% of loss for the given period.
Volatility was left at 14.37%, however, over the last 30 days, the volatility rate increased by 17.05%, as shares sank -44.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.81% lower at present.
During the last 5 trading sessions, MBIO fell by -33.48%, which changed the moving average for the period of 200-days by -90.19% in comparison to the 20-day moving average, which settled at $0.9783. In addition, Mustang Bio Inc saw -48.26% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBIO
The total capital return value is set at -20.82. Equity return is now at value -222.44, with -93.68 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at -19.81. The debt to equity ratio resting at 20.31. The interest coverage ratio of the stock is -37.81.
Currently, EBITDA for the company is -48.5 million with net debt to EBITDA at 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To put it simply, Mustang Bio Inc (MBIO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
